Key result
Pre-treatment with rosuvastatin and telmisartan, alone or in combination, significantly improved biomarker levels and histological damage in doxorubicin-induced acute cardiotoxicity.
Why the study?
Cardiac injury is the main dose-limiting factor for doxorubicin use as an anticancer agent, linked to complex mechanisms including oxidative stress, mitochondrial damage, and apoptosis.
Does pre-treatment with rosuvastatin and telmisartan reduce doxorubicin-induced acute cardiotoxicity?
Population
Cardiomyocytes
Comparison
Pre-treatment with rosuvastatin and telmisartan in different doses alone or in combination vs Dox-induced acute cardiotoxicity
Authors
Loading...
Hypothesis-generating for doxorubicin cardiotoxicity prevention; should not change practice pending human trials.
Does pre-treatment with rosuvastatin and telmisartan reduce doxorubicin-induced acute cardiotoxicity?
Rosuvastatin and telmisartan, alone or in combination, demonstrate cardioprotective effects against doxorubicin-induced acute cardiotoxicity in a preclinical model.
Al‐kuraishy et al. (2022) studied Doxorubicin-induced acute cardiotoxicity. Rosuvastatin and telmisartan was evaluated on Biomarkers of cardiac damage (cTnI, LDH), oxidative stress (MDA), inflammation (IL-17), and histopathological changes. Pre-treatment with rosuvastatin and telmisartan, alone or in combination, significantly improved biomarker levels and histological damage in doxorubicin-induced acute cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: